E. Thomas Corcoran - 29 May 2026 Form 4 Insider Report for PHIBRO ANIMAL HEALTH CORP (PAHC)

Reporting relationship: Director
Issuer ticker: PAHC
Reported as of: 29 May 2026
Net transaction value: +$317,700
SEC form: 4
Accepted by SEC: 02 Jun 2026, 18:56:16 UTC
Prior SEC filing: 26 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Judith Weinstein, as Attorney-in-Fact for E. Thomas Corcoran

Key filing fact

E. Thomas Corcoran filed Form 4 for PHIBRO ANIMAL HEALTH CORP (PAHC) on 02 Jun 2026.

Key facts

This page summarizes E. Thomas Corcoran's Form 4 filing for PHIBRO ANIMAL HEALTH CORP (PAHC).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 02 Jun 2026, 18:56.

Change

Previous filing in this sequence was filed on 26 Feb 2025.
Current net transaction value: +$317,700.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001191763 Primary reporting owner

CORCORAN E THOMAS

Relationship: Director
Address: 300 FRANK W. BURR BLVD.,, STE. 21, TEANECK
Signature: /s/ Judith Weinstein, as Attorney-in-Fact for E. Thomas Corcoran
Signature date: 02 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PAHC transaction

Class A Common Stock

Purchase

Transaction value: $317,700
Shares: +10,000
Change %: +32%
Price: $31.77
Shares after: 41,459
Date: 29 May 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $31.66 to $31.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range.

Footnote F2

Includes 1,459 shares acquired under a dividend reinvestment plan sponsored by the Reporting Person's broker.